A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

In this 2-part study, Part 1 is a multicenter, open-label, safety, tolerability, and systemic
exposure evaluation to Sunitinib in escalating doses of a single IVT injection of GB-102,
while Part 2 is a multicenter, double-masked, randomized (1:1:1), parallel‑group, safety, and
efficacy evaluation of repeated IVT injections of 2 dose levels of GB‑102 compared with
aflibercept.

Key Inclusion Criteria:

1. Males or females of any race, ≥ 50 years of age

2. Presence of an active CNV lesion secondary to AMD treated with at least 3 monthly
injections of an anti-VEGF agent (aflibercept, bevacizumab, or ranibizumab)

3. Evidence of increased vascular permeability and/or loss of visual acuity

Key Exclusion Criteria:

1. History, within 6 months prior to screening, of any of the following: myocardial
infarction, any cardiac event requiring hospitalization, treatment for acute
congestive heart failure, transient ischemic attack, or stroke

2. Uncontrolled hypertension, diabetes mellitus, IOP, hypothyroidism, or hyperthyroidism

3. Chronic renal disease

4. Abnormal liver function

5. Women who are pregnant or lactating